A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
Findings Based on Randomized Study of Danish Women with High-Risk, Early Breast Cancer Published in npj Breast Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. , (Nasdaq: VCYT) today announced the publication of a large, retrospective study in which the Danish Breast Cancer
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
2019 Total Revenue Grew 31% to $120.4 Million ; Genomic Test Volume Grew 25% to 39,612 Achieved Fourth Quarter 2019 Positive Cash Flow from Operations Fourth Quarter Acquisition Positions Company for Global Expansion Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif.
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation March 2020